Barometer Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Barometer Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,548	Closed	-$1.63M	–	193
2024 Q3	$1.63M	Buy	+1,548	New	+$1.72M	0.47%	42
2020 Q4	–	Sell	-5,525	Closed	-$3.09M	–	184
2020 Q3	$3.09M	Sell	5,525 -3,590	-39%	-$2.18M	0.63%	51
2020 Q2	$5.68M	Buy	9,115 +8,415	+1,202%	+$4.78M	1.06%	38
2020 Q1	$342K	Buy	+700	New	+$289K	0.1%	79
2017 Q3	–	Sell	-12,710	Closed	-$6.24M	–	191
2017 Q2	$6.24M	Buy	+12,710	New	+$5.56M	0.63%	47

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Barometer Capital Management's REGN Position: Q4 2024 in Review

Barometer Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 1,548 shares — an estimated $1.63M sold.

Barometer Capital Management first reported a position in REGN in Q2 2017 and held it in 5 quarters. The position peaked at $6.24M in Q2 2017. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Barometer Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Barometer Capital Management sold 1,548 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $1.63M.
Barometer Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2017 and held it in 5 quarters.
Barometer Capital Management's Regeneron Pharmaceuticals position peaked at $6.24M in Q2 2017.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Barometer Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.